2Qiao YL, Tockman MS, Li L, et al. A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in china. Cancer Epidemiol Biomarkers Prey, 1997, 6: 893-900.
3Shapiro HM. Practical flow cytometry. Third edition. New York:Wiley-liss, 1994. 388-390.
4Schonbeck U, Libby P. The CD40/CD154 teceptor/ligand dyad.Cell Mol Life Sci, 2001,58:4-43.
5Zhang H, Melamed J, Wei P, et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun, 2003,3:2.
6Sasaki H, Yukiue H, Mizuno K, et al. Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer .Int J Clin Oncol, 2003, 8: 79-82.
7Ozer G, Altinel M, Kocak B, et al. Potential value of soluble intercellular adhesion molecule-1 in the serum of patients with bladder cancer. Urol Int, 2003,70:167-171.
8Walker PR, Saas P, Dietrich PY. Role of fas lisand (CD95L) in immune escape: the tumor cell strikes back. J Immunol, 1997,158:4521-4524.
9Martinez-Arribas F, Nunez-Villar M J, Lucas AR, et al.Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients . Anticancer Res,2003, 23:565-568.
10Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p^53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res, 1994, 54:4855-4878.
